Physician profile
Christopher Frank Wagener
NPI 1669489829
$200,572.78
in general payments reported to CMS, 2019-2025
8 companies · $22K in 2025
The $22K reported for 2025 was more than what 92% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $30K · 2021: $19K · 2022: $35K · 2023: $12K · 2024: $6,907 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $41K · Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $40,951.36 |
| Food and Beverage | $164.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corelink, LLC | $69,425.21 | 2019-2023 | |
| Zimvie INC. | $46,661.15 | 2022-2023 | |
| Zimmer Biomet Holdings, INC. | $28,525.39 | 2019-2020 | |
| Spine Wave, INC. | $22,832.81 | 2019-2025 | Exceed Biplanar Expandable Interbody System |
| Ulrich Medical USA, INC. | $21,899.73 | 2019-2021 | |
| Highridge Medical LLC | $11,101.04 | 2024-2025 | Trelloss-C Sa |
| Pfizer INC. | $105.88 | 2019-2024 | |
| Pacira Pharmaceuticals Incorporated | $21.57 | 2025 | Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wagener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.